Pharma Mar - EU Taxonomy Data: Eligible & Aligned Revenues, CAPEX & OPEX

Pharma Mar's EU Taxonomy Data Preview

In 2025, Pharma Mar was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.

The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.

Pharma Mar has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Pharma Mar are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.

turnoveropexcapex

Metric	2025	2024	2023	2022-2019
Total Taxonomy Aligned Turnover	0%^a	0%^b	0%^c
Total Taxonomy Eligible Turnover	36%^a	38.1%^b	44.7%^c

Metric	2025	2024	2023	2022-2019
Total Taxonomy Aligned Opex	0%^a	0%^b	0%^c
Total Taxonomy Eligible Opex	0.1%^a	0.1%^b	0.2%^c

Metric	2025	2024	2023
Total Taxonomy Aligned Capex	2.7%^a	0.5%^b	0%^c
Total Taxonomy Eligible Capex	3.7%^a	5.8%^b	52.5%^c
Activity Level Taxonomy Aligned Capex (2 activities)
6.15 CCM - Infrastructure enabling low-carbon road transport and public transport	0.3%^a	N/A	N/A
7.6 CCM/CCA - Installation, maintenance and repair of renewable energy technologies	2.4%^a	0.5%^b	N/A

Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Verified Sources Behind Pharma Mar’s EU Taxonomy Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Pharma Mar's Consolidated Non-Financial Report 2025

b. Pharma Mar's Annual Report 2024

c. Pharma Mar's Consolidated Non-Financial Report 2023

d. Pharma Mar's Consolidated Non-Financial Report 2022

Insights into Pharma Mar's Revenues from Sustainable Activities

In 2025, Pharma Mar reported EU Taxonomy-eligible revenues of EUR 79.68 million, representing 36% of its total turnover. Of this amount, EUR 0 of Pharma Mar's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).^a

Insights into Pharma Mar's CAPEX from Sustainable Activities

In 2025, Pharma Mar reported EU Taxonomy-eligible CAPEX of EUR 428,000,representing 3.7% of its total CAPEX. Of this amount, EUR 314,000 of Pharma Mar's CAPEX was classified as EU Taxonomy-aligned, indicating that 2.7% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).^a

Pharma Mar's Taxonomy-Eligible Capex Over Time

Total Taxonomy Eligible Capex
Total Taxonomy Aligned Capex

Have Pharma Mar's increased its investment in sustainable activities over time?

Compared to the previous year (2024), Pharma Mar's taxonomy-aligned CAPEX increased by 440%,highlighting Pharma Mar's strengthened commitment to investing in environmentally sustainable activities or improving how such investments are classified and reported under the EU Taxonomy.^{a, b}

How much of Pharma Mar's capital expenditure (CAPEX) is eligible under the EU Taxonomy?

In 2025, Pharma Mar reported that EUR 428,000 of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 3.7% of the company's total CAPEX. Of this amount, EUR 314,000 (2.7% of total CAPEX) was classified as Taxonomy-aligned. This means that 1% of Pharma Mar's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).^a

How much of Pharma Mar's eligible CAPEX is aligned with the EU Taxonomy?

In 2025, Pharma Mar reported that EUR 314,000 of its CAPEX was aligned under the EU Taxonomy, representing 2.7% of its total capital investment.^a

This low alignment reflects that Pharma Mar is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.

Pharma Mar's Eligibility & Alignment Overview

Pharma Mar's Contribution to Environmental Objectives

Total Taxonomy Aligned Capex

How is Pharma Mar's taxonomy-aligned CAPEX distributed across the EU environmental objectives?

In 2025, Pharma Mar reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectives^a:

Climate Change Mitigation: 2.7%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%

How much Pharma Mar is investing in climate-related solutions?

In 2025, Pharma Mar allocated EUR 314,172 of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 2.7% of the company's total capital expenditure,indicating that Pharma Marhas only marginally directed its capital expenditure toward climate-related activities, suggesting limited alignment with climate objectives.^a

Insights into Pharma Mar's OPEX from Sustainable Activities

In 2025, Pharma Mar reported EU Taxonomy-eligible OPEX of EUR 76,000,representing 0.1% of its total operating expenses (OPEX). Of this amount, EUR 6,000 of Pharma Mar's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).^a

Pharma Mar's Contribution to Environmental Objectives

How is Pharma Mar's taxonomy-aligned OPEX distributed across the EU environmental objectives?

In 2025, Pharma Mar reported that its taxonomy-aligned operational expenditure (OPEX) was distributed across the following EU environmental objectives^a:

Climate Change Mitigation: 0%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%

How much of Pharma Mar's operational budget supports climate-related solutions?

In 2025, Pharma Mar allocated EUR 0 of its OPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 0% of the company's total OPEX,indicating that Pharma Marhas only a limited share of operational expenditure aligned with climate goals, signaling early-stage or minimal integration of climate objectives into its routine activities.^a

Pharma Mar SA

Pharma Mar's EU Taxonomy Data Preview

Verified Sources Behind Pharma Mar’s EU Taxonomy Data

Insights into Pharma Mar's Revenues from Sustainable Activities

Insights into Pharma Mar's CAPEX from Sustainable Activities

Pharma Mar's Taxonomy-Eligible Capex Over Time

Have Pharma Mar's increased its investment in sustainable activities over time?

How much of Pharma Mar's capital expenditure (CAPEX) is eligible under the EU Taxonomy?

How much of Pharma Mar's eligible CAPEX is aligned with the EU Taxonomy?

Pharma Mar's Eligibility & Alignment Overview

Pharma Mar's Contribution to Environmental Objectives

How is Pharma Mar's taxonomy-aligned CAPEX distributed across the EU environmental objectives?

How much Pharma Mar is investing in climate-related solutions?

Insights into Pharma Mar's OPEX from Sustainable Activities

Pharma Mar's Contribution to Environmental Objectives

How is Pharma Mar's taxonomy-aligned OPEX distributed across the EU environmental objectives?

How much of Pharma Mar's operational budget supports climate-related solutions?

Explore Peer Companies

Atrys Health SA

Valneva SE

Lakefront Biotherapeutics NV

argenx SE

Ucb SA

Genmab A/S

Pharma Mar SA

Pharma Mar's EU Taxonomy Data Preview

Verified Sources Behind Pharma Mar’s EU Taxonomy Data

Insights into Pharma Mar's Revenues from Sustainable Activities

Insights into Pharma Mar's CAPEX from Sustainable Activities

Pharma Mar's Taxonomy-Eligible Capex Over Time

Have Pharma Mar's increased its investment in sustainable activities over time?

How much of Pharma Mar's capital expenditure (CAPEX) is eligible under the EU Taxonomy?

How much of Pharma Mar's eligible CAPEX is aligned with the EU Taxonomy?

Pharma Mar's Eligibility & Alignment Overview

Pharma Mar's Contribution to Environmental Objectives

How is Pharma Mar's taxonomy-aligned CAPEX distributed across the EU environmental objectives?

How much Pharma Mar is investing in climate-related solutions?

Insights into Pharma Mar's OPEX from Sustainable Activities

Pharma Mar's Contribution to Environmental Objectives

How is Pharma Mar's taxonomy-aligned OPEX distributed across the EU environmental objectives?

How much of Pharma Mar's operational budget supports climate-related solutions?

Explore Peer Companies

Atrys Health SA

Valneva SE

Lakefront Biotherapeutics NV

argenx SE

Ucb SA

Genmab A/S

Account Restricted